LoginGet started

How Big Pharma is Extending the Pandemic

Tom Nicholas・56 minutes read

Two years after the identification of SARS-CoV-2, wealthy countries have successfully rolled out COVID-19 vaccines, but global vaccination efforts are hindered by unequal distribution and profit-driven pharmaceutical companies, sparking debates over patents and access to life-saving technologies. The World Trade Organization's TRIPS Agreement has favored rich countries and pharmaceuticals, leading to concerns about equitable access, with civil society organizations advocating for freeing COVID-19 vaccines from profit-driven companies to save lives globally.

Insights

  • Wealthy countries have secured surplus COVID-19 vaccines, while poorer nations struggle to access an adequate supply, leading to global vaccine inequality and hindering efforts to combat the pandemic effectively.
  • The debate surrounding intellectual property rights, pharmaceutical profits, and equitable vaccine distribution has intensified, with initiatives like COVAX prioritizing profit over global health equity, raising concerns about the current international system's ability to address public health crises equitably.

Get key ideas from YouTube videos. It’s free

Recent questions

  • What is the main challenge hindering global vaccination efforts?

    The central issue hindering global vaccination efforts is the unequal distribution of vaccines. Despite the production of 1.5 billion doses monthly, wealthy nations are buying up most vaccines, leaving poorer countries undersupplied. This imbalance is exacerbated by wealthy countries like the UK, US, and EU having surplus doses even after vaccinating their populations. COVAX, a global initiative for equitable vaccine distribution, aimed to ensure fair pricing and distribution but faced challenges due to vaccine nationalism. Pharmaceutical companies profited from varying vaccine prices, with some countries paying significantly more for doses. COVAX has shifted from a multilateral project to a charitable aid scheme reliant on donations from wealthy nations. Despite initial promises, many countries have failed to fulfill their vaccine donation pledges to COVAX, hindering global vaccination efforts.

  • How are pharmaceutical companies profiting from COVID-19 vaccines?

    Pharmaceutical companies have profited significantly from COVID-19 vaccines. Companies like Pfizer and Moderna have made billions in profit from their vaccines. AstraZeneca initially committed to selling its vaccine at-cost but later shifted to for-profit contracts. Governments provided substantial funding for vaccine development, covering a large portion of costs. Challenges in implementing vaccination programs include manufacturing large quantities of vaccines, logistical issues in distribution, and addressing vaccine hesitancy. Manufacturing new types of vaccines at scale has required building new supply chains and facilities. Distributing vaccines globally involves complex logistics, including maintaining proper storage temperatures. Vaccine hesitancy varies among populations, influenced by factors like distrust in government, historical contexts, and religious beliefs.

  • What is COVAX and its role in global vaccination efforts?

    COVAX is a global initiative for equitable vaccine distribution that aimed to ensure fair pricing and distribution but faced challenges due to vaccine nationalism. Despite its flaws, COVAX allows pharmaceutical companies to profit while appearing charitable. COVAX, involving CEPI and Gavi, leans towards protecting vaccine patents and profits, unlike C-TAP. The Gates Foundation, a key funder of CEPI and Gavi, supports intellectual property rights, influencing COVAX's direction. COVAX has shifted from a multilateral project to a charitable aid scheme reliant on donations from wealthy nations. Despite initial promises, many countries have failed to fulfill their vaccine donation pledges to COVAX, hindering global vaccination efforts. The central issue hindering global vaccination efforts is the unequal distribution of vaccines.

  • What is C-TAP and how does it differ from COVAX?

    C-TAP, run by the World Health Organization and Costa Rica, aims to share patent-protected technologies and knowledge for vaccine development. C-TAP's voluntary scheme would have facilitated vaccine production and lowered costs through sharing technologies. Despite its potential benefits, C-TAP's failure prompts discussions on whether pharmaceutical companies should withhold life-saving technologies. COVAX, launched a month after C-TAP, overshadowed it, with a more profit-oriented approach. COVAX, involving CEPI and Gavi, leans towards protecting vaccine patents and profits, unlike C-TAP. The Gates Foundation, a key funder of CEPI and Gavi, supports intellectual property rights, influencing COVAX's direction. COVAX has shifted from a multilateral project to a charitable aid scheme reliant on donations from wealthy nations.

  • How has the TRIPS Agreement impacted access to essential medicines?

    The TRIPS Agreement of the WTO changed patent laws, allowing for patents on chemical compounds of medicines. Developing countries previously relied on reverse-engineering drugs to provide affordable alternatives. The TRIPS Agreement led to developing countries paying $60 billion more annually for essential medicines. During the AIDS crisis, the TRIPS Agreement restricted access to affordable HIV medications in Africa. Efforts by countries in the Global South and NGOs aim to liberate COVID-19 vaccines from profiteering pharmaceutical companies through a temporary waiver of certain TRIPS Agreement aspects. Wealthy countries have enough vaccines to administer booster shots to their populations, prioritizing their safety. Countries with significant pharmaceutical industries defend patent rights to protect their national capitalist interests. Despite opposition, rich countries' commitment to safeguarding Big Pharma's profits has halted the proposed patent waiver.

Related videos

Summary

00:00

Global vaccine inequality fuels prolonged pandemic

  • December 2021 marked 2 years since the identification of SARS-CoV-2 in Wuhan, China.
  • Public health measures like social distancing and lockdowns became normalized due to the pandemic.
  • Wealthy countries have rolled out COVID-19 vaccines to significant portions of their populations.
  • Despite advances, the pandemic continues with new, more transmissible variants emerging.
  • Large pharmaceutical companies have profited significantly from COVID-19 vaccines.
  • Companies like Pfizer and Moderna have made billions in profit from their vaccines.
  • AstraZeneca initially committed to selling its vaccine at-cost but later shifted to for-profit contracts.
  • Governments provided substantial funding for vaccine development, covering a large portion of costs.
  • Vaccination efforts have been successful in wealthier countries but lag in lower-income nations.
  • Vaccine inequality poses a global threat, allowing new variants to emerge and prolong the pandemic.

15:22

Innovating Vaccines: Challenges and Exploitation

  • Edison is often seen as a businessman rather than an inventor, but credit should be given for turning the lightbulb into a societal innovation.
  • Vaccines for COVID-19 are considered brilliant inventions, with early requirements for approval set at over 50% effectiveness.
  • Pfizer-BioNTech, Moderna, Sputnik V, and UK vaccines are highly effective against COVID-19 and its variants.
  • Invention is just the first step; exploiting vaccines' potential by administering them is crucial.
  • The term "exploitation" in innovation can have both positive and negative connotations, especially in business management.
  • Pharmaceutical companies have prioritized profit over fully utilizing vaccines' potential to end the pandemic.
  • Challenges in implementing vaccination programs include manufacturing large quantities of vaccines, logistical issues in distribution, and addressing vaccine hesitancy.
  • Manufacturing new types of vaccines at scale has required building new supply chains and facilities.
  • Distributing vaccines globally involves complex logistics, including maintaining proper storage temperatures.
  • Vaccine hesitancy varies among populations, influenced by factors like distrust in government, historical contexts, and religious beliefs.

30:21

Unequal Vaccine Distribution Hinders Global Efforts

  • Vaccine donations from wealthy countries to poorer countries are erratic and often consist of surplus vaccines close to expiration.
  • Some vaccine donations to developing countries arrive just weeks before their expiration date, leading to wastage.
  • Organizations like UNICEF are aiding in distributing specialized freezers to hold mRNA vaccines in developing countries.
  • Despite global vaccine production of 1.5 billion doses monthly, wealthy nations are buying up most vaccines, leaving poorer countries undersupplied.
  • Wealthy countries like the UK, US, and EU have surplus doses even after vaccinating their populations.
  • The central issue hindering global vaccination efforts is the unequal distribution of vaccines.
  • COVAX, a global initiative for equitable vaccine distribution, aimed to ensure fair pricing and distribution but faced challenges due to vaccine nationalism.
  • Pharmaceutical companies profited from varying vaccine prices, with some countries paying significantly more for doses.
  • COVAX has shifted from a multilateral project to a charitable aid scheme reliant on donations from wealthy nations.
  • Despite initial promises, many countries have failed to fulfill their vaccine donation pledges to COVAX, hindering global vaccination efforts.

44:58

Global debate: Should companies profit from vaccines?

  • The COVID-19 Technologies Access Pool (C-TAP) challenges the idea of companies profiting from life-saving medicines.
  • C-TAP, run by the World Health Organization and Costa Rica, aims to share patent-protected technologies and knowledge for vaccine development.
  • C-TAP's voluntary scheme would have facilitated vaccine production and lowered costs through sharing technologies.
  • COVAX, launched a month after C-TAP, overshadowed it, with a more profit-oriented approach.
  • COVAX, involving CEPI and Gavi, leans towards protecting vaccine patents and profits, unlike C-TAP.
  • The Gates Foundation, a key funder of CEPI and Gavi, supports intellectual property rights, influencing COVAX's direction.
  • Bill Gates' defense of intellectual property rights, even during the COVID-19 pandemic, aligns with his past stances.
  • COVAX, despite its flaws, allows pharmaceutical companies to profit while appearing charitable.
  • C-TAP's failure prompts discussions on whether pharmaceutical companies should withhold life-saving technologies.
  • The global debate on pharmaceutical companies' rights to withhold vaccines from poorer countries intensifies, questioning the current system upheld by international treaties and agreements.

59:42

Global South challenges WTO rules on medicines

  • The World Trade Organization establishes basic minimum standards for trade policies among countries.
  • Conflict often arises between poorer countries in the Global South and wealthier countries in the Global North within the WTO.
  • Rich countries with larger delegations at the WTO headquarters in Geneva have more influence over setting rules.
  • Intellectual property and pharmaceuticals are heavily favored by WTO rules, benefiting rich countries over poor ones.
  • The TRIPS Agreement of the WTO changed patent laws, allowing for patents on chemical compounds of medicines.
  • Developing countries previously relied on reverse-engineering drugs to provide affordable alternatives.
  • The TRIPS Agreement led to developing countries paying $60 billion more annually for essential medicines.
  • During the AIDS crisis, the TRIPS Agreement restricted access to affordable HIV medications in Africa.
  • South Africa passed legislation allowing for compulsory licenses on essential medicines, facing opposition from the US and EU.
  • Efforts by countries in the Global South and NGOs aim to liberate COVID-19 vaccines from profiteering pharmaceutical companies through a temporary waiver of certain TRIPS Agreement aspects.

01:14:38

Global push for equitable COVID-19 vaccine distribution.

  • Wealthy countries have enough vaccines to administer booster shots to their populations, prioritizing their safety.
  • Countries with significant pharmaceutical industries defend patent rights to protect their national capitalist interests.
  • Despite opposition, rich countries' commitment to safeguarding Big Pharma's profits has halted the proposed patent waiver.
  • Civil society organizations, including Amnesty International and Oxfam, continue to advocate for freeing COVID-19 vaccines from profit-driven pharmaceutical companies.
  • The withholding of vaccines from vulnerable regions exacerbates the pandemic, emphasizing the need for equitable distribution to save lives globally.
Channel avatarChannel avatarChannel avatarChannel avatarChannel avatar

Try it yourself — It’s free.